Oncology

Latest News

Patients in the cemiplimab group had superior disease-free survival vs placebo. | Image credit: Medical Works - stock.adobe.com
Cemiplimab Improves Disease-Free Survival in High-Risk, Advanced CSCC

June 13th 2025

Cemiplimab improved disease-free survival in patients with high-risk cutaneous squamous cell carcinoma (CSCC) and performed well in patients with advanced CSCC in the real-world setting.

The approval covers use of pembrolizumab as a single agent in the neoadjuvant setting, followed by adjuvant treatment with pembrolizumab in combination with radiotherapy with or without cisplatin after surgery, and then continued as a single agent. | Image credit: wladimir1804-stock.adobe.com
FDA Approves Perioperative Pembrolizumab in Resectable HNSCC

June 13th 2025

FDA approval-Olivier Le Moal-stock.adobe.com.jpeg
Mitomycin Intravesical Solution Gains FDA Approval for Recurrent Low-Grade NMIBC

June 12th 2025

AJMC
Utilization and Costs Among Oncologists Participating in a Private Insurance Shared Savings Model

June 11th 2025

The new report suggests the C5a-C5aRq axis might be a useful target in combination with existing therapies for cutaneous squamous cell carcinoma. | Image credit: vladimircaribb - stock.adobe.com
C5aR1 Flagged as Biomarker in Cutaneous Squamous Cell Carcinoma

June 7th 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

Site Logo
October 15th 2018

Survey of NCI-Designated Cancer Centers Finds Most Are Out-of-Network on Exchanges

Alyssa Schatz, MSW Katy Winckworth-Prejsnar, MPH
The National Comprehensive Cancer Network (NCCN) in collaboration with Avalere Health present survey results examining the experiences National Cancer Institute (NCI)-designated cancer centers have had with the marketplaces, the implications for patients' access to cancer care, and proposed policy solutions.
Three Genetic Types Drive Higher Prevalence of MM in African Americans
October 14th 2018

Three Genetic Types Drive Higher Prevalence of MM in African Americans

Laura Joszt, MA
Multiple myeloma (MM) occurs 2 to 3 times more frequently in Americans of African descent than in Americans of European descent, and a new study has identified 3 gene types that account for this disparity.
ACOs Had No Significant Impact on Spending for Patients With Cancer
October 14th 2018

ACOs Had No Significant Impact on Spending for Patients With Cancer

Laura Joszt, MA
Accountable care organizations (ACOs) have not had a significant impact on cancer care costs and utilization. While cancer care costs did decline from before the introduction of ACOs to after, there was no significant difference in spending decreases between ACO practices and non-ACO practices caring for patients with cancer.
Know the Risk: 5 Breast Cancer Risk Factors
October 13th 2018

Know the Risk: 5 Breast Cancer Risk Factors

Samantha DiGrande
Here are 5 breast cancer risk factors for Breast Cancer Awareness Month.
The US Oncology Network Announces Highly Positive MIPS Results for 2017
October 12th 2018

The US Oncology Network Announces Highly Positive MIPS Results for 2017

Laura Joszt, MA
Practices in the US Oncology Network received an average positive payment adjustment under the Merit-based Incentive Payment System (MIPS) of 1.90% for performance in 2017, and 99% of the Network’s physicians were in the top tier of performers. The maximum allowable adjustment is 2.02%. The adjustment based on a clinician’s performance in 2017 impacts the clinician's Medicare reimbursement for 2019.
Nobel Prize Winner Dr James Allison Discusses the Need to Fund More Fundamental Science
October 12th 2018

Nobel Prize Winner Dr James Allison Discusses the Need to Fund More Fundamental Science

Major discoveries only happen when there is funding for fundamental science, said James Allison, PhD, chair of the Department of Immunology, the Vivian L. Smith Distinguished Chair in Immunology, director of the Parker Institute for Cancer Research, executive director of the Immunotherapy Platform at MD Anderson Cancer Center, and 2018 Nobel Prize cowinner in Medicine. He explained that he never would have discovered how to use the CTLA-4 protein to treat cancer if he hadn’t been trying to understand the mechanisms of T-cell activation.
Tisagenlecleucel's High Price Aligns With Its Benefit in Pediatric B-ALL, Study Finds
October 11th 2018

Tisagenlecleucel's High Price Aligns With Its Benefit in Pediatric B-ALL, Study Finds

Laura Joszt, MA
Tisagenlecleucel's high price is aligned with the benefit the chimeric antigen receptor T-cell therapy provides over a patient's life. Approximately 40% of patients treated are expected to be long-term survivors.
NCCN Releases Patient Guidelines for Neuroendocrine Tumors
October 10th 2018

NCCN Releases Patient Guidelines for Neuroendocrine Tumors

Samantha DiGrande
This week, the National Comprehensive Cancer Network (NCCN) published new guidelines for patients centered around neuroendocrine tumors.
FDA Approves Libtayo to Treat Second Most Common Skin Cancer
October 10th 2018

FDA Approves Libtayo to Treat Second Most Common Skin Cancer

Samantha DiGrande
Last week, the FDA granted approval to immune checkpoint inhibitor cemiplimab-rwlc, to be sold as Libtayo, for the treatment of metastatic cutaneous squamous cell carcinoma (CSCC), or in patients with locally advanced CSCC who are not candidates for curative surgery or curative radiation.
Some Metro Areas Facing Shortages of Oncologists in Coming Years, Report Says
October 10th 2018

Some Metro Areas Facing Shortages of Oncologists in Coming Years, Report Says

Allison Inserro
A medical social network for physicians said it has compiled data that pinpoint the top 50 metropolitan areas where shortages of oncologists are expected to occur in the coming years. Doximity said the findings in its 2018 National Oncologists Workforce report are drawn from retirement trends, the percentage of state-trained specialists, and the prevalence of breast cancer.
Does Transcriptional Loss of HLA Cause Immunotherapy Resistance?
October 8th 2018

Does Transcriptional Loss of HLA Cause Immunotherapy Resistance?

David Bai
The development of resistance to immunotherapy is poorly understood and is detrimental to patients who relapse on multiple lines of treatment. Transcriptional downregulation of class 1 human leukocyte antigen (HLA) may contribute to the developed resistance of immunotherapies, including checkpoint inhibitors, and warrants further investigation, according to a study published in Nature Communications.
Site Logo
October 7th 2018

A Comprehensive Look at Updates, Developments in NETs

Jaime Rosenberg
During a session at the North American Neuroendocrine Tumor Society annual meeting, held October 4-6 in Seattle, Washington, Thorvardur Halfdanarson, MD, associate professor of medicine and consultant in medical oncology, Mayo Clinic, outlined the biggest news and updates in the treatment of neuroendocrine tumors (NETs).
Site Logo
October 7th 2018

An Update on Lung NET Guidelines

Jaime Rosenberg
During a session at the North American Neuroendocrine Tumor Society (NANETS) annual meeting, held October 4-6 in Seattle, Washington, Sukhmani Padda, MD, assistant professor of medicine, Stanford University Medical Center, gave an overview of updates made to lung neuroendocrine tumor guidelines.
Dr Thorvardur Halfdanarson Outlines New, Exciting Developments in Treatment of NETs
October 7th 2018

Dr Thorvardur Halfdanarson Outlines New, Exciting Developments in Treatment of NETs

Thorvardur Halfdanarson, MD, associate professor of medicine and consultant in medical oncology, Mayo Clinic, discusses peptide receptor radionuclide therapy and other new and exciting developments in the treatment of neuroendocrine tumors (NETs).
Site Logo
October 6th 2018

Sequencing of Lanreotide Can Improve Outcomes in Patients With Advanced GEP-NETs

AJMC Staff
A retrospective analysis of clinical charts across multiple institutions has found that transitioning patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs) to receive lanreotide after octreotide can be a potential therapeutic option.
Dr Scott Paulson on Current Challenges in the NETs Treatment Landscape
October 6th 2018

Dr Scott Paulson on Current Challenges in the NETs Treatment Landscape

The biggest challenge we have right now is how to sequence all of these therapies and how to pick the right patient to sequence those treatments, explained Scott Paulson, MD, co-director of the Gastrointestinal Research Program for The US Oncology Network, medical director for the Neuroendocrine Research and Treatment Center at Baylor Charles A. Sammons Cancer Center, Baylor University Medical Center.
Site Logo
October 6th 2018

Merkel Cell Carcinoma in the United States: Prognostics and Treatment Options

Jaime Rosenberg
Narrowing in on neuroendocrine skin cancer, a session at the North American Neuroendocrine Tumor Society annual meeting October 4-6 in Seattle, Washington, took an in-depth look at prognostics and treatment options for Merkel cell carcinoma in the United States.
Site Logo
October 6th 2018

Debating Best First-Line Treatment in Well-Differentiated G3 NENs

Jaime Rosenberg
During a session at the North American Neuroendocrine Tumor Society annual meeting October 4-6 in Seattle, Washington, panelists debated whether newer targeted agents should be considered for first-line treatment in well-differentiated G3 neuroendocrine neoplasms (NENs), and if the standard of care—cytotoxic therapy—should still play a role in first-line treatment.
Cancer Types Can Impact How Well Providers May Perform Under OCM
October 5th 2018

Cancer Types Can Impact How Well Providers May Perform Under OCM

Laura Joszt, MA
The type of cancer a provider treats can determine how well he or she performs under the Oncology Care Model (OCM), according to research from Avalere Health that was presented at the American Society of Clinical Oncology Quality Care Symposium.
Site Logo
October 5th 2018

Examining the Benefits of Integrative Oncology, Nutrition in NETs

Jaime Rosenberg
During a session at the North American Neuroendocrine Tumor Society annual meeting October 4-6 in Seattle, Washington, panelists discussed the benefits of integrative oncology and nutrition for patients with neuroendocrine tumors.
Dr Heloisa Soares Discusses the Roles of Somatostatin Analogs in GEP-NETs
October 5th 2018

Dr Heloisa Soares Discusses the Roles of Somatostatin Analogs in GEP-NETs

Somatostatin analogs have 2 roles in gastroenteropancreatic neuroendocrine tumors (GEP-NETS): treating symptoms related to the tumors and controlling tumor growth, explained Heloisa Soares, MD, assistant professor, University of New Mexico Cancer Center-Albuquerque.
Site Logo
October 5th 2018

Analysis Demonstrates Effectiveness, Patient Satisfaction With Lanreotide in GEP-NETs

Jaime Rosenberg
An interim analysis of somatostatin analog lanreotide depot presented at the North American Neuroendocrine Tumor Society annual meeting, held October 4-6 in Seattle, Washington, found that the treatment was effective in disease control and most patients were satisfied with the treatment.
Site Logo
October 5th 2018

Measuring Quality of Life Among Patients With Neuroendocrine Tumors

Jaime Rosenberg
Two studies presented at the North American Neuroendocrine Tumor Society annual meeting October 4-6 in Seattle, Washington assessed different tools for determining quality of life among patients with neuroendocrine tumors (NETs).
Preventing Antimicrobial Complications, Ensuring Stewardship in Cancer Care
October 5th 2018

Preventing Antimicrobial Complications, Ensuring Stewardship in Cancer Care

Allison Inserro
This week, infectious disease specialists from different organizations are meeting in San Francisco for ID Week, an annual conference focused on many different infectious disease topics and their intersection with cancer, HIV, respiratory diseases, and more. Two abstracts presented results about what is needed to prevent complications in cancer care, one about patients with acute myeloid leukemia (AML) with prolonged neutropenia, and one examining the frequency of antimicrobial complications following initiation of palliative chemotherapy.
Site Logo
October 4th 2018

Making the Leap to Prospective Risk in Value-Based Oncology Care

Mary Caffrey
The Institute for Value-Based Medicine travels to New York City to learn how technology and trust are key to making the leap to two-sided risk.
Site Logo
October 4th 2018

Recent Study on Site of Care Has Severe Limitations

Lucio N. Gordan, MD Debra Patt, MD
The outpatient community oncology setting is consistently less costly for cancer treatment as opposed to the outpatient hospital setting.
Site Logo
October 4th 2018

The Authors Respond and Stand Behind Their Findings

Yamini Kalidindi, MHA Jeah Jung, PhD Roger Feldman, PhD
Our study provides the first evidence on site-specific Medicare spending on chemotherapy adjusting for patient comorbid illnesses, cancer type, and other cancer-related risks.
FDA Approves Once-Weekly Dose of Kyprolis for R/R Multiple Myeloma
October 3rd 2018

FDA Approves Once-Weekly Dose of Kyprolis for R/R Multiple Myeloma

Laura Joszt, MA
A once-weekly dose of carfilzomib (Kyprolis) in combination with dexamethasone has been approved to treat patients with relapsed or refractory (R/R) multiple myeloma. The approved regimen improved progression-free survival and had a better overall response rate than a twice-weekly regimen.
Employers Take a Vested Interest in Healthcare
October 3rd 2018

Employers Take a Vested Interest in Healthcare

Employers may not look forward to purchasing healthcare, but they are in the position to transform the market. More employers are getting more involved in healthcare by championing alternative payment models and other services to their employees.
People Living With HIV Have Higher Risk of First and Second Primary Cancer Incidence
October 2nd 2018

People Living With HIV Have Higher Risk of First and Second Primary Cancer Incidence

Jaime Rosenberg
A new study has found that people living with HIV are at an increased risk of both first and second primary cancer incidence.
<1
...
373839404142434445
...
186>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo